October 4, 2021 07:18 AM EDT
Pharma

Three gener­ic firms shell out $447M more to set­tle fed­er­al price fix­ing al­le­ga­tions

Zachary Brennan

Senior Editor

Gener­ic drug firms Taro Phar­ma­ceu­ti­cals USA, No­var­tis’ San­doz, and Apo­tex have agreed with the US De­part­ment of Jus­tice to pay $447.2 mil­lion on top of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times